For many patients, the benefits of GLP-1 therapyimproved blood sugar, lower cardiovascular risk, sustainable weight lossare significant
These medications mimic the hormone glucagon-like peptide-1, which helps regulate appetite and insulin secretion, offering a powerful tool for those struggling with obesity or weight-related health conditions
However, Lilly recently (April 21, 2023) registered a new Phase 3b trial (SURMOUNT-5) that will compare Mounjaro against Wegovy in patients with obesity or overweight with weight-related health conditions
The presented findings are consistent with research on the species used in Pendulums products, so although the studies were conducted or sponsored by Pendulum, they dont assert any seriously doubtful conclusions
Karlsson, T., Hadizadeh, F., Rask-Andersen, M., Johansson, & Ek, W